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ABSTRACT
Expression of Beta Protein 1 (BP1), a homeotic transcription factor, increases 
during breast cancer progression and may be associated with tumor aggressiveness. 
In our present work, we investigate the influence of BP1 on breast tumor formation 
and size in vitro and in vivo. Cells overexpressing BP1 showed higher viability when 
grown in the absence of serum (p < 0.05), greater invasive potential (p < 0.05) and 
formed larger colonies (p < 0.004) compared with the controls. To determine the 
influence of BP1 overexpression on tumor characteristics, MCF-7 cells transfected 
with either empty vector (V1) or overexpressor plasmids (O2 and O4) were injected 
into the fat pads of athymic nude mice. Tumors grew larger in mice receiving O2 
or O4 cells than in mice receiving V1 cells. Moreover, BP1 mRNA expression levels 
were positively correlated with tumor size in patients (p = 0.01). Interestingly, 20% 
of mice injected with O2 or O4 cells developed tumors in the absence of estrogen, 
while no mice receiving V1 cells developed tumors. Several mechanisms of estrogen 
independent tumor formation related to BP1 were established. These data are 
consistent with the fact that expression of breast cancer anti-estrogen resistance 
1 (BCAR1) was increased in O2 compared to V1 cells (p < 0.01). Importantly, O2 
cells exhibited increased proliferation when treated with tamoxifen, while V1 cells 
showed growth inhibition. Overall, BP1 overexpresssion in MCF-7 breast cancer cells 
leads to increased cell growth, estrogen-independent tumor formation, and increased 
proliferation. These findings suggest that BP1 may be an important biomarker and 
therapeutic target in ER positive breast cancer. 
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INTRODUCTION
Beta Protein 1(BP1), an isoform of DLX4, belongs 
to the homeobox family of genes, master regulatory genes 
implicated in early development and cell differentiation 
that are frequently deregulated in cancer [1, 2]. Aberrant 
expression of BP1 has been shown in women with breast 
cancer. HOXB7-transduced SkBr3 cell lines developed 
tumors in nude mice in the absence of irradiation, while 
control mice injected with SkBr3 cells did not form tumors 
under those conditions [3]. Importantly, repression of 
HOXA5 in breast cancer resulted in the loss of expression 
of the tumor suppressor p53 [4]. Moreover, constitutive 
expression of HOXA1 in MCF7 cells led to increased 
anchorage-independent growth and tumor formation in 
mice [5]. BP1 directly activates the anti-apoptotic gene 
BCL-2 and results in resistance to TNF-α. In sporadic 
breast cancer, BP1 negatively regulates the expression of 
breast cancer anti-estrogen resistance 1 (BRCA1) through 
binding to its intron, suggesting that overexpression of 
BP1 might be a potential inhibitor of BRCA1. Therefore, 
targeting BP1 may provide a new avenue for breast cancer 
management [6]. 
BP1 belongs to the Distal-less subfamily of the 
homeobox gene family [7]. In our earlier study, BP1 
expression was examined in untreated invasive ductal 
breast carcinoma (IDC) using semi-quantitative RT-PCR 
[8]. Overall, BP1 mRNA expression was found in 80% 
of breast tumors, with an 11% rate of low BP1 mRNA 
in normal tissues, while 100% of ER-negative tumors 
expressed BP1. These data suggest BP1 might be a useful 
target for therapy in patients with ER-negative tumors. 
In a follow-up study, we examined IDC cases from the 
Armed Forces Institute of Pathology which included 
women from around the world [9]. Eighty one percent 
of invasive ductal carcinomas were BP1 positive by 
immunostaining, indicating excellent agreement between 
BP1 RNA expression (80%) and protein expression (81%). 
Estrogens are crucial hormones involved not only in 
normal breast development but also in carcinogenesis of 
breast epithelium and progression of breast cancer [10]. 
Estrogens act through a specific receptor, the estrogen 
receptor (ER). Once activated by estrogen, ER forms 
a transcriptional complex with various co-activators 
and co-repressors on target gene promoters to regulate 
their expression [11] ER-negative breast cancers are 
unresponsive to anti-estrogen therapy. In general, these 
tumors have a higher histologic grade and a higher 
proliferative rate and are associated with poorer prognosis. 
In this paper we found estrogen independence associated 
with high BP1 expression in ER-positive tumors in cell 
lines and in mice. To determine the molecular mechanism 
that contributes in part or in whole to BP1-related breast 
cancer aggressiveness in ER+ tumors, in vitro experiments 
were carried out. Here we present a novel model of ER 
regulation and estrogen independence by BP1. 
RESULTS
Increased levels of BP1 are associated with 
a more aggressive phenotype in MCF-7 cells 
in vitro 
MCF-7 cells containing an empty vector (V1) or a 
plasmid stably overexpressing BP1 cDNA under control 
of the CMV promoter (O2 and O4) were tested using 
classical assays which assess the oncogenic characteristics 
of cells. These cell lines were previously shown to express 
increased levels of BP1 mRNA and protein [12]. In the 
first assay, cells were grown in the absence of serum to 
test growth factor independence. By day seven in the 
absence of serum (Figure 1A), cell lines overexpressing 
BP1 (O2 and O4) showed approximately two to three-fold 
higher viability compared with V1, a statistically significant 
difference (p < 0.05). These data suggest that high BP1 
levels may protect against cell death in the absence of 
serum, consistent with the increased BCL-2 expression in 
BP1-overexpressing MCF-cells, as reported [12]. 
Growth in soft agar was utilized to determine 
the anchorage independent growth of BP1- transfected 
MCF- 7 cells. This assay is considered a reliable method 
for detecting the malignant potential of cells [13]. While 
the total number of colonies was similar for the cell lines 
(V1 = 150, O2 = 161, O4 = 152), the cells overexpressing 
BP1 produced larger and more rapidly growing colonies 
(Figure 1B and 1C). Ninety-five percent of the colonies 
formed by V1 cells were equal to or less than 0.2 mm, 
while 88–93% of O2 and O4 colonies were greater 
than 0.2 mm. Both the O2 and the O4 cell lines had a 
significantly higher distribution of colony sizes compared 
to the V1 cell lines (p < 0.0001, Wilcoxon Rank Sum test). 
Even by day 4, the colonies derived from O2 and O4 were 
noticeably larger than those from V1 (Figure 1C). 
Whereas MCF-7 cells are poorly invasive through 
Matrigel [14], we wished to determine whether BP1 could 
modulate their invasiveness. As shown in Figure 1D, O2 and 
O4 cells overexpressing BP1 increased invasion of MCF-7 
cells by approximately 16-fold compared with control V1 
cells, which was statistically significant (p < 0.05). These 
data suggest that BP1 levels may affect the metastatic 
potential of breast cancer, as previously demonstrated in 
ER-negative Hs578T breast cancer cells [15].
Characteristics of tumor growth in mice 
It has previously been established that MCF-7 
cells grow as a solid tumor when placed in the mammary 
glands of mice supplemented with estrogen [16]. To 
determine whether high BP1 levels would influence tumor 
characteristics, we injected V1, O2 or O4 cells into cleared 
fat pads of athymic nude mice, with 10 mice per group. 
Palpable tumors were present at 45 days post-surgery in the 
mammary glands of mice supplemented with an estrogen 
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pellet (Figure 2A). Due to the relatively small number of 
mice, data from mice injected with O2 and O4 cells were 
combined. Tumors derived from O2 and O4 cells, labeled 
BP1 (Figure 2A), appeared to grow at a faster rate and 
were larger by day 58 than tumors from control V1 cells, 
but the small number of tumors precluded significance 
testing. No distant metastases were observed for any mice 
at the time of sacrifice. BP1 expression was retained in 
the tumors, shown by protein expression analysis. In mice 
supplemented with estrogen, BP1 expression was higher 
in tumors derived from O2 and O4 cells than in tumors 
derived from V1 cells (Figure 2B, red staining cells). 
Human breast tumor size correlates with BP1 
expression 
The possible clinical relevance of BP1 expression 
level with respect to tumor size in breast cancer patients 
was determined. Real-time PCR was used to measure 
the levels of expression of BP1 mRNA from 31 tumor 
samples. The levels of BP1 expression, relative to 18S 
RNA, ranged over 300-fold (Figure 3). For comparison, 
RNA was extracted from five normal breast tissues; BP1 
levels ranged from 0.010 to 0.060 relative to 18S RNA. 
We found a positive correlation (r = 0.40, p = 0.02) 
between [log] BP1 expression and [log] tumor size. 
After statistically controlling for age and race, the partial 
correlation coefficient remained statistically significant 
(partial r = 0.49, p = 0.01). Thus, there is an association 
between higher BP1 mRNA expression levels and tumor 
size in patients. 
BP1 expression is associated with estrogen 
independence 
In general, MCF-7 cells require exogenous 
estrogen to form tumors in nude mice [16]. However, 
approximately 20% of the mice implanted with cells 
Figure 1: Overexpression of BP1 in MCF-7 cells is associated with aggressiveness. (A) Growth in the absence of serum. V1, 
O2 and O4 cell lines were grown without serum for seven days and cell number was measured using MTT assays. Data was normalized 
against day 0, which was set as 100%. Asterisks denote a statistical significance of p < 0.05 as compared to V1. (B) Colony formation in soft 
agar. V1, O2 and O4 cell lines were grown in soft agar as described in Materials and Methods. (C) Photomicrographs of cells grown in soft 
agar for four or 13 days. (D) Invasion of cells through Matrigel. BP1 overexpressing cell lines (O2 and O4) exhibited higher invasiveness 
compared to the empty vector control cell lines (V1) (p < 0.05). Three fields of unit area on each membrane were counted for cell numbers 
and the experiments were repeated twice. 
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stably transfected with BP1 (O2 or O4) were able to form 
tumors in the absence of estrogen, in contrast to 0% of 
mice injected with V1 cells (Table 1), but this difference 
was not statistically significant, probably due small sample 
size. Thus, BP1 overexpression in MCF-7 cells may 
induce estrogen-independent tumorigenesis in mice. 
BP1 regulates ER via two mechanisms
Direct regulation
A computer search revealed a consensus BP1 
binding site [7] located in the first intron (IVS1) of 
the ER gene. An electrophoretic mobility shift assay 
(EMSA) verified that BP1 binds to this site in vitro. The 
consensus-binding site within a short stretch of IVS1 was 
used as a probe. As shown in Figure 4A, BP1 binds to 
the probe (lane 2, arrow). The shifted band is specific, 
demonstrated by competition with the unlabeled probe 
DNA (lanes 3 and 4) but not with non-specific DNA 
(lanes 5 and 6). A ChIP assay was performed to validate 
the EMSA results. DNA was precipitated using the BP1 
antibody (anti-BP1) with O2 DNA or whole DNA (input) 
as positive controls, but not the IgG negative control 
(IgG control) (Figure 4B). The relative quantity of IVS1 
precipitated by BP1 antibody is much higher in O2 cells 
than in V1 cells. The qRT-PCR data (Figure 4C, *p < 0.01) 
and Western blot analysis (Figure 4D) suggest that binding 
of BP1 transcriptionally upregulates ER. 
Indirect regulation
Previously, we showed that BP1 negatively regulates 
BRCA1 [6]. P300 is a known histone acetyl transferase 
(HAT) protein which shares a dynamic relationship with 
BRCA1 and ER [17, 18]. This led us to investigate the 
relationship between BP1 and p300. We found a putative 
BP1 binding region in the first intron of the EP300 gene. 
Figure 2: Tumor growth in mice is enhanced by increased BP1 expression. (A) Tumor size. Nude mice supplemented with 
a cholesterol-based estrogen pellet were injected in the cleared mammary fat pad with V1, O2 or O4 cell lines. Tumors were measured 
twice weekly and allowed to grow up to 58 days. (B) Immunostaining of tumors with anti-BP1 antibody. Anti-BP1 antibody was used to 
immunostain tumor sections. Since no tumors derived from V1 cells formed in the absence of an estrogen supplement, all sections are from 
estrogen supplemented mice. Figures are shown at 300X magnification. 
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A ChIP assay was performed to verify the binding of 
BP1 to the first intron of P300. Figure 5A and 5B show that 
BP1 binds to the P300 gene in the first intronic region in 
MCF-7 cell derivatives and T47D cell lines, respectively. 
T47D cells are ER+ cell lines that have high endogenous 
levels of BP1 proteins [8]. BP1 binding is significantly 
higher in O2 cells than in V1 cells (Figure 5A). The qRT-
PCR data (Figure 5C, *p < 0.05) and Western blot analysis 
(Figure 5D) show increased expression of p300 in cells 
overexpressing BP1 (O2) compared to V1 cells. Each 
experiment was repeated at least three times. Thus, BP1 
transcriptionally upregulates P300.
Increased levels of BP1 expression are associated 
with tamoxifen resistance
Our in vivo experiments indicate that BP1 may be a 
contributing factor to estrogen independence. Consistent 
with this, we observed elevated levels of ER in O2 
cells. To determine if increased BP1 expression imparts 
tamoxifen resistance, we performed MTT assays over a 
period of 7 days with V1 and O2 cell lines (Figure 6A). 
O2 cells were more resistant to tamoxifen than V1 cells 
on days 1–7 (p < 0.0001). Pairwise comparative adjusted 
means and 95% confidence intervals are shown. The O2 
Table 1: Estrogen dependence of mammary tumor formation in mice correlates with BP1 expression
Cell Type Injected With Estrogen Without Estrogen
V1 4/10 (40%) 0/10 (0%)
O2 10/15 (67%) 2/10 (20%)
O4 7/11 (64%) 2/10 (20%)
MCF-7 cell lines O2 and O4, which overexpress BP1, were compared with V1, a cell line containing the empty vector. The 
percentage of mice in each category is shown in parentheses.
Figure 3: BP1 expression levels in breast tumors. RNA was extracted from 31 frozen tumors, followed by real-time PCR analysis. 
BP1 levels were normalized to 18S RNA. For comparison, RNA was extracted from five normal frozen breast tissues. 
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means are consistently higher than the V1 means, with the 
only overlap in confidence intervals occurring on Day 7. 
Factorial analysis of covariance showed that the Condition 
x Day interaction was not statistically significant 
(p = 0.33). The lack of interaction between Condition and 
Day are apparent in Figure 6A, where the time trends are 
very similar for the O2 and V1 conditions. 
Real-time PCR was used to determine the levels 
of BCAR1 mRNA, a marker of tamoxifen resistance 
[19], comparing V1 and O2 cells. As can be seen from 
Figure 6B, BCAR1 expression was almost two fold higher 
in O2 than in V1 cells (p < 0.01). 
DISCUSSION
By a number of different measures, MCF-7 cells 
overexpressing BP1 were more aggressive: they grew in 
the absence of serum, formed larger colonies in soft agar, 
were relatively more infiltrative in an invasion assay and 
could form tumors in mice without external estrogen 
supplementation. This result was consistent with our 
earlier findings that BP1 positive breast tumors have a 
higher proliferation rate than BP1 negative tumors [9]. We 
also demonstrated in our earlier study that overexpression 
of BP1 significantly enhanced cell proliferation and 
metastatic potential in ER-negative Hs578T cells [15]. 
The observation that tumors developed in mice without 
estrogen supplementation was intriguing. Mechanisms of 
estrogen independence/tamoxifen resistance are not yet 
fully understood. Evidence in the literature points out that 
tumors acquire tamoxifen resistance in variety of ways, 
including but not limited to constitutive activation of ER by 
phosphorylation via increased growth factor signaling (non-
genomic signaling pathway), leading to ligand independent 
activation of ER and thus insensitivity to estrogen, increased 
expression of co-activators, conversion of ER positive cells 
to ER negativity, lack of the 46 kDa ER protein, presence of 
the 36 kDa ER protein [20–24] or inappropriate increases in 
Figure 4: BP1 binds to and regulates ER. (A) Binding of BP1 to IVS1 of the estrogen receptor. Electrophoretic mobility shift assays 
were performed to detect potential binding of in vitro transcribed and translated BP1 to a consensus binding sequence located in IVS1 of 
the estrogen receptor. Binding of BP1 to a 32P end-labeled dsDNA probe containing the putative BP1 binding site and surrounding sequence 
is observed as a shifted band (arrow). Lane 1, wheat germ extract (WG) alone incubated with the probe. Lane 2, BP1 incubated with the 
probe. Lanes 3 and 4, unlabeled ER DNA (ER) was added to the incubation mixture containing BP1 protein at 500 X or 1000X molar 
excess, respectively. Lanes 5 and 6, a nonspecific negative control (NC) DNA to which BP1 protein does not bind was added at a 500 X or 
1000X molar excess. (B) ChIP assay. DNA was precipitated using either the BP1 antibody (anti-BP1) or IgG negative control (IgG control) 
and whole DNA as positive control (input). The quantity of IVS1 DNA precipitated by BP1 antibody was compared in BP1 overexpressing 
cells (O2) and the empty vector (V1). (C) qRT-PCR. mRNA level of ER was measured by qRT-PCR comparing empty vector (V1) and BP1 
overexpressor (O2) (*p < 0.01). Experiments were performed in triplicate. (D) Western blot analysis. Immunoblotting was performed with 
protein extracts from V1 and O2 cells as described in Materials and Methods. 
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ER protein levels via increased stability [25–28]. Tamoxifen 
resistance/estrogen independence in BP1 overexpressing 
cells is due in part to increased stability. Also, ER, p300 and 
BRCA1 share a dynamic relationship, with BRCA1 inhibiting 
ER via ubiquitination, and p300 competitively stabilizing 
ER via acetylation [17, 29, 30]. Here we found that BP1 
activates EP300; it is known that BP1 represses BRCA1 [6]. 
Thus, BP1 increases ER protein levels by both (i) a direct 
mechanism: BP1 transcriptionally upregulates ER and (ii) 
an indirect mechanism: BP1 transcriptionally upregulates 
p300, thus aiding increased stability of ER (Figure 7). We 
also demonstrate that cells overexpressing BP1 are more 
resistant to tamoxifen and express the tamoxifen resistant 
marker BCAR1; we have found a consensus BP1 binding 
site in BCAR1, suggesting that BP1 may directly regulate 
BCAR1.
Other HB genes have been implicated in an altered 
response to tamoxifen. Breast cancer cells overexpressing 
HOXB7 or HOXB13 show repression of the estrogen 
receptor leading to estrogen independence and resistance 
to tamoxifen [31, 32]. In contrast, here we show that 
BP1, also a HB gene, has the ability to confer tamoxifen 
insensitivity by both transcriptionally upregulating and 
stabilizing ER protein. 
Our previous data demonstrated that the frequency 
of BP1 positivity, and the distribution and intensity of 
BP1 expression, increased with the progression of tumor 
development (normal→ hyperplasia→ in situ→ invasive), 
from a few randomly distributed BP1 positive cell clusters 
in normal controls to the vast majority of cells in the 
invasive tumors showing distinct BP1 immunoreactivity 
[9]. Other indicators of relative aggressive behavior are 
associated with BP1 expression in breast tumors. BP1 
positivity is associated with (i) high tumor grade [33], 
a classical indicator of tumor aggressiveness [34]; (ii) 
tumors of African American women [8], known to show 
relative aggressive clinical behavior and associated with 
increased mortality [35, 36]; (iii) inflammatory breast 
cancer (IBC), a form of breast cancer with poor survival 
[37, 38], where we found that 100% of IBC tumors were 
Figure 5: BP1 binds to and upregulates EP300. (A, B) ChIP assays. Chromatin immunoprecipitation was performed as described 
above to verify the binding of BP1 to the first intron of the EP300 gene in MCF-7 cell derivatives and T47D cell lines, respectively. 
(C) qRT-PCR. mRNA levels of p300 were measured by qRT-PCR comparing MCF-7 cells containing an empty vector (V1) and cells 
overexpressing BP1 (O2) (*p < 0.05). Experiments were performed in triplicate. (D) Western blot analysis. Immunoblotting was performed 
to determine the levels of p300 protein expression in V1 and O2 cells.
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Figure 6: BP1 increases tamoxifen resistance. (A) MTT assay. V1 and O2 cells were challenged with 3 uM tamoxifen over seven 
days, as described in Materials and Methods. The 95% confidence limits are shown on the adjusted means. (B) mRNA levels of the 
tamoxifen resistance marker, BCAR1 (breast cancer anti-resistance). BP1 O2 cells have increased levels of BCAR1 mRNA compared with 
V1 cells (*p < 0.01).
Figure 7: Model of BP1 regulation of ER. Dotted lines indicate a transcriptional mechanism, while solid lines indicate translational 
control (A: acetylation, U: Ubiquitination). BP1 binds to and activates EP300; p300 protein, which acetylates and “rescues” ER from 
BRCA1-mediated ubiquitination, is then up-regulated. Simultaneously, BP1 binds and transcriptionally activates ER. The increased ER 
protein expression and stability result in increased tamoxifen resistance.
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BP1 positive, as well as nine lymph nodes from BP1 
positive, metastatic IBC tumors [39]; (iv) increased 
expression of the proliferation marker Ki67 in BP1 
positive breast and prostate tumors [9, 40]; (v) decreased 
apoptosis due to increased expression of BCL-2 [12]; (vi) 
increased expression of VEGF in BP1 positive ovarian 
tumors (BP1 is called DLX4 in Hara et al. [41]). ChIP-
on-chip (Chromatin Immunoprecipitation on microarray 
promoter chip) combined with expression microarray 
studies have demonstrated that BP1 may regulate VEGF 
expression in Hs578T breast cancer cells as well [42]; 
(vii) epithelial to mesenchymal transition [43]. BP1 is 
expressed in a high percentage of ER negative tumors as 
well [8]. Here we show that BP1 overexpression correlates 
with increased metastatic potential, larger tumor size, less 
dependence on growth factors and resistance to tamoxifen 
treatment. A picture of the possible clinical importance of 
BP1 is now emerging.
Based on gene expression profiles, attempts have 
been made to classify breast tumors, with luminal 
A being most common subtype of breast cancer 
representing almost 50–60% of all diagnosed cases [44]. 
Luminal A tumors are generally characterized by low 
expression of the proliferation marker Ki67, sustained 
expression of ER, PR and BCL-2 and generally low 
HER2 expression [44, 45]. These types of tumors tend 
to have a more favorable tumor biology, good prognosis, 
low histological grade, respond well to tamoxifen/
endocrine therapy and form smaller tumors [45]. 
Luminal B tumors constitute between 10–20% of all 
breast cancer cases. There are a number of characteristics 
in common between Luminal B tumors and BP1 positive 
tumors, as illustrated in this paper: (a) increased 
expression of proliferation genes, such as Ki67 [9, 44, 
45]; (b) ER+, HER2 +/– and PR+/– in Luminal B tumors 
and frequent (73%) BP1 positivity in ER+ tumors [8, 
44, 45]; (c) poor prognosis and high grade [33, 44, 45]; 
(d) reduced sensitivity to tamoxifen ([44, 45] and shown 
here associated with BP1 levels) and (e) larger tumors 
([44, 45] and shown here for BP1). Therefore, we 
speculate that BP1 overexpression in Luminal A subtype 
cells can “propel” those cells to display more Luminal 
B-like characteristics. Further study with clinical patient 
samples is necessary to determine whether BP1 is a 
biomarker for Luminal B type tumors. 
Our current data, along with previously published 
data, suggest that not only does BP1 expression increase 
with breast tumor progression but it is also involved in 
regulating gene expression patterns in tumors, driving 
them towards a more aggressive subtype. In particular, 
increased BP1 expression is associated with larger 
tumors, increased invasiveness of MCF-7 cells, and 
possibly with increased resistance to tamoxifen. Future 
clinical studies will provide important insights on BP1 
as a biomarker and potential therapeutic target in ER 
positive breast cancer.
MATERIALS AND METHODS
Cell lines and viability assays 
MCF-7 cells and derivatives that overexpress BP1 
were described [12]. MCF-7 cells, as well as the empty 
vector and BP1 overexpressing MCF-7 cell lines, were 
maintained in RPMI 1640 containing 10% FBS and 1% 
penicillin/streptomycin (P/S), supplemented with 500μg/
ml of G418. For viability assays, 2000 cells/well were 
seeded in triplicate in a 96-well plate and allowed to 
attach overnight. Media was replaced with serum-free 
RPMI 1640 the next day and was changed on day 3. For 
tamoxifen assays, 2000 cells/wells were seeded in a 96-
well plate and allowed to attach overnight. The media was 
replaced with phenol red free RPMI 1640 containing 5% 
charcoal stripped serum (CSS) and 1% P/S. The media 
was changed after 24 hours and 3µM tamoxifen was added 
(Sigma, St. Louis, MO, USA). Tamoxifen containing 
media was replaced every 48 hours and readings were 
taken from day 1 to day 7. Growth was measured by the 
3-(4,5-dimethylthiazol-2-yl)-(2,3-diphenyltetrazolium) 
bromide dye conversion assay (Sigma) at 570 nm. T47D 
cell lines were grown and maintained in RPMI 1640 
containing 10% FBS and 1% penicillin/streptomycin. 
Cell growth in soft agar
12,500 cells/ml were suspended in 0.3% agar 
supplemented with DMEM and 10% FBS and layered 
over 1ml of a 0.8% agar/medium base [46]. Cells were 
allowed to grow over a 14-day period; colonies were 
stained with nitroblue tetrazolium and counted using an 
Artek 880 colony counter. 
Invasion assays
The cell invasive capacity was estimated using 
BioCoat Matrigel Invasion Chambers (8 mm pores, 
24 wells) (BD Bioscience, Bedford, MA, USA) as 
described previously [15]. In brief, cells stably transfected 
with an empty vector or with BP1 cDNA plasmids 
were resuspended in serum-free DMEM medium 
(2.5 × 105 cells/ml) and seeded in the top chamber of pre-
wet inserts. After 48 h incubation, cells that migrated to 
the bottom surface of the insert were stained with Diff-
Quick staining solution and quantified. The number of 
migrating cells was determined by counting five non-
overlapping random fields on each chamber; four to five 
chambers were counted for each experimental point.
Tumor formation in mice
The use of mice in this study was approved by 
the NIH Institutional Animal Care and Use Committee 
(IACUC). All procedures were conducted in accordance 
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with the NIH Guide for the Care and Use of Laboratory 
Animals. Athymic nude mice were maintained on a 12 hr 
light/12 hr dark schedule with free access to laboratory 
chow and water. 2 × 106cells were injected into the cleared 
mammary fat pads of 4–6 week old female athymic nude 
mice [47]. At the same time, some of the mice were also 
implanted subcutaneously with a 10 mg cholesterol-based 
pellet containing 0.72 mg of 17-β-estradiol (Innovative 
Research of America, Sarasota, FL, USA). Tumors were 
measured at the indicated times in two dimensions using 
calipers. At sacrifice, tumors were either frozen or fixed in 
10% normal buffered formalin. 
Clinical samples
Human breast tumor samples were obtained from 
The George Washington University Department of 
Pathology with IRB approval. Breast tissue samples 
0.5– 1.0 cm in diameter were obtained from frozen surgical 
resection specimens and characterized pathologically.
Electrophoretic mobility shift assays (EMSA) 
assays
EMSA was performed as described earlier [6, 7]. 
Complementary sequences in the first intervening 
sequence (IVS1) of the ER were annealed and 5′-end-
labeled with 32P-ATP using T4 kinase (Invitrogen, Grand 
Island, NY, USA). The Wheat Germ Coupled Transcription 
/Translation kit (Promega, Madison, WI, USA) was 
used to generate BP1 protein from the plasmid pGEM7 
containing the BP1 open reading frame. Unlabeled 
competitor oligonucleotides were added at 500X or 1000X 
molar excess to the binding reactions. The following DNA 
sequences were used as probes: ER: 
5′-GGCAAAATGCAGCTCTTCCTATATGTATAC 
CCTGAATCTC-3′; negative control (NC):
5′-TCTTAGAGGGAGGGCTGAGGGTTTGAAG 
TCCAACTCCTAAGCC-3′.
Chromatin-immunoprecipitation (ChIP) assays 
The BP1 consensus binding site (5′-WTCWATATG-3′) 
on EP300 [7] was predicted using the CISTER program 
[48]. Primers, flanking the putative BP1 binding site, 
were designed using primer3plus [49] tool and verified by 
primer-BLAST [50]. The primers used for ChIP assay are 
as follows: 5′-GGAGCATCCTCAGATTTTGG-3′ (EP300-
Forward) and 5′-TGCCTTAACTATCTGCTGATTTTC-3′ 
(EP300-Reverse). The ChIP protocol was performed using 
the Millipore ChIP kit (Millipore, Billerica, MA, USA) as 
described previously [6, 42]. Briefly, BP1-overexpressing 
MCF-7 or T47D cells were crosslinked at 80% confluence 
in 10 mL RPMI 1640 media with 1% formaldehyde for 
ten minutes at 37ºC. Cells were washed twice with cold 
PBS containing 1x complete mini protease inhibitor 
(Roche Applied Science, Indianapolis, IN, USA), lysed in 
SDS lysis buffer and incubated for fifteen minutes on ice. 
Chromatin was sheared by sonication for 10 pulses, twice. 
Equal amounts of DNA were used as test and negative 
controls, and 1 µg was used as the input control. 10 µg 
of BP1 antibody (Bethyl Labs, Montgomery, TX, USA) 
or equal amounts of normal rabbit IgG (Cell signaling, 
Danvers, MA, USA ) were added along with salmon 
sperm DNA/Protein G PLUS/Protein A agarose beads, 
and incubated overnight at 4C. Further isolation and 
purification of the precipitated DNA was done according 
to Millipore’s protocol. Isolated DNA was resuspended 
in Tris-EDTA buffer for use in PCR. Platinum superscript 
master mix was used with a 10 µM final concentration of 
each primer and 1 µg of DNA as input or 5 µl of isolated/
precipitated DNA in a final reaction volume of 45 µl. PCR 
was run for 40 cycles. The PCR product was analyzed on a 
2% agarose gel and visualized.
Real-time PCR assays 
Total RNA was prepared using the RNeasy Mini 
Kit (Qiagen Inc, Valencia, CA. USA). RNA samples 
underwent DNase I treatment (Promega, Madison, WI, 
USA) prior to first-strand cDNA synthesis with random 
hexamer primers using the Superscript II First-Strand 
cDNA Synthesis System (Invitrogen, Grand Island, 
NY, USA). Real-time PCR was carried out using the 
ABI 7300 model sequence detection system (Applied 
Biosystem, Foster City, CA, USA) with SYBR Green I 
PCR Mastermix (BioRad, Hercules, CA, USA). Primers 
for ER and EP300 were published [51–53]. Primers 
for BP1 were designed using Primer-BLAST and are 
as follows: 5′-CCTCCCCCAATTTGTCCTACTC-3′ 
(forward) and 5′-GGTTGCTGGCAGGACAGGTA-3′ 
(reverse). The amplification program included an initial 
denaturation at 95°C for 10 min., followed by 40 cycles of 
a two-stage PCR consisting of 95°C for 15s and 60°C for 
1 min. Specificity for PCR amplifications was verified by 
observing a single peak dissociation curve for each gene. 
One microliter of the reverse transcribed cDNA was used 
for each real-time PCR reaction and all reactions were 
performed in triplicate. The expression values of genes 
from different samples were calculated by normalizing 
with 18S RNA and relative quantitation values were 
plotted.
Immunoblotting assays
Cells were grown to 70%–80% confluency and 
proteins extracted as previously described [12]. 30–65 µg 
of proteins were loaded on 4–20% SDS-PAGE gels 
(Bio-Rad, Hercules, CA, USA) and transferred to 
nitrocellulose membranes. Blots were probed overnight 
with rabbit anti-BP1 (Bethyl Labs, Montgomery, TX, 
USA) at a 1:5000 dilution, with rabbit antiER-α (Bethyl 
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labs, Montgomery, TX, USA) at a 1:1000 dilution, mouse 
anti-p300 (Millipore, Billerica, MA, USA) at a 1:500 
dilution, or mouse anti-beta-actin (Sigma, St. Louis, MO, 
USA) at a 1:5000 dilution. After washing, blots were 
incubated with either horseradish peroxidase-linked goat 
anti-mouse (1:2500 dilution) or goat anti-rabbit secondary 
antibodies (1:15,000 dilution). Signals were detected using 
SuperSignal West Dura Extended Duration Substrate 
(Pierce, Rockford, IL, USA). 
Statistical analyses
For analysis of mouse data, due to the smaller 
sample sizes, data were first pooled for the mice receiving 
the two BP1- overexpressing cell lines when tested against 
the control mice. For the test of colony size differences, 
results are based on the pooled data from six independent 
replications (two experimental replications of three wells 
each). For tamoxifen experiments, in order to adjust for 
any ethanol (EtOH) effects on optical density, scores 
were calculated by subtraction (subtracting mean optical 
density under the EtOH condition for each day for O2 
and V1 from the tamoxifen condition scores) and by ratio 
(dividing the tamoxifen condition scores by the mean 
optical density under the EtOH condition for each day for 
O2 and V1). The ratio adjustment method was used for all 
subsequent analyses because of greater homoscedasticity 
and reasonable evidence of normality. The statistical 
test of mean differences on study condition (O2 vs V1), 
follow-up day, and Condition x Day interaction was by 
factorial analysis of covariance. The qPCR data for ER 
and p300 were analyzed by one-sample t-test.
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